Associated Papers
Association of SLCO1B3 and SLCO1B1 Polymorphisms with Methotrexate Efficacy and Toxicity in Saudi Rheumatoid Arthritis Patients.
Magadmi R et al.
Pharmaceuticals (basel, Switzerland), 2025
Impacts of Pharmacokinetic Gene Polymorphisms on Steady-State Plasma Concentrations of Simvastatin in Thai Population.
Tipnoppanon S et al.
Clinical and Translational Science, 2025
EP-01: Association of genetic polymorphisms of OATP with susceptibility to hepatocellular carcinoma in hepatitis C patients who achieved SVR by direct acting antivirals.
Altintas ZM et al.
Hepatology Forum, 2021
Role of Genetic Variations in the Hepatic Handling of Drugs.
Marin JJG et al.
International Journal of Molecular Sciences, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.
Yang F et al.
Scientific Reports, 2018
Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.
Yee SW et al.
Clinical Pharmacology and Therapeutics, 2018
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Sortica VA et al.
Pharmacogenomics, 2017
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population.
Chae YJ et al.
Journal of Pharmaceutical Sciences, 2012
Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions.
Clarke JD et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Pharmacogenetics of membrane transporters: an update on current approaches.
Sissung TM et al.
Molecular Biotechnology, 2010
Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M et al.
Therapeutic Drug Monitoring, 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Smith NF et al.
Clinical Pharmacology and Therapeutics, 2007
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature.
Anabtawi N et al.
Expert Opinion on Drug Metabolism & Toxicology, 0